C4 Therapeutics Inc.

37.91+0.8300+2.24%Vol 940.93K1Y Perf 48.41%
Jun 18th, 2021 16:00 DELAYED
BID37.92 ASK38.00
Open37.19 Previous Close37.08
Pre-Market- After-Market-
 - -  - -%
Target Price
53.25 
Analyst Rating
— — 0.00
Potential %
40.46 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.43
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.64B 
Earnings Rating
Price Range Ratio 52W %
58.37 
Earnings Date
12th Aug 2021

Today's Price Range

36.6538.72

52W Range

22.4048.97

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Neutral
Performance
1 Week
-10.12%
1 Month
10.43%
3 Months
-2.17%
6 Months
17.88%
1 Year
48.41%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CCCC37.910.83002.24
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.63-0.4922.22
Q03 2020-1.16-17.55-1 412.93
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.60
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume940.93K
Shares Outstanding43.20M
Trades Count10.12K
Dollar Volume5.25M
Avg. Volume330.40K
Avg. Weekly Volume909.20K
Avg. Monthly Volume536.18K
Avg. Quarterly Volume444.53K

C4 Therapeutics Inc. (NASDAQ: CCCC) stock closed at 37.91 per share at the end of the most recent trading day (a 2.24% change compared to the prior day closing price) with a volume of 941.41K shares and market capitalization of 1.64B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 99 people. C4 Therapeutics Inc. CEO is Andrew Hirsch.

The one-year performance of C4 Therapeutics Inc. stock is 48.41%, while year-to-date (YTD) performance is 14.43%. CCCC stock has a five-year performance of %. Its 52-week range is between 22.4 and 48.97, which gives CCCC stock a 52-week price range ratio of 58.37%

C4 Therapeutics Inc. currently has a PE ratio of -6.90, a price-to-book (PB) ratio of 6.91, a price-to-sale (PS) ratio of 53.81, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -19.59%, a ROC of -25.03% and a ROE of -27.79%. The company’s profit margin is -%, its EBITDA margin is -214.30%, and its revenue ttm is $33.81 Million , which makes it $0.78 revenue per share.

Of the last four earnings reports from C4 Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. C4 Therapeutics Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for C4 Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for C4 Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

C4 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

C4 Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 40.85, ATR14 : 2.47, CCI20 : -36.33, Chaikin Money Flow : -0.02, MACD : 0.85, Money Flow Index : 51.41, ROC : -0.29, RSI : 49.85, STOCH (14,3) : 30.04, STOCH RSI : 0.14, UO : 45.06, Williams %R : -69.96), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of C4 Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

C4 Therapeutics Inc.

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

CEO: Andrew Hirsch

Telephone: +1 617 231-0700

Address: 490 Arsenal Way, Watertown 02472, MA, US

Number of employees: 99

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

50%50%

News

Stocktwits